J&J/Cordis' ExoSeal
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary Cordis will enter the vascular closure device market in June with the European debut of its ExoSeal system. The bioabsorbable polyglycolic acid plug system, which is designed to close femoral artery puncture sites, received CE-mark approval in May. "An advantage compared to other devices is the procedural sheath does not need to be changed, which helps promote patient comfort," Cordis claims. Competing systems include Abbott's StarClose and St. Jude Medical's AngioSeal
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.